Tumor Markers | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0352 governing tumor marker coverage policy, effective March 28, 2026. Here's what billing teams need to know before that date.

Tumor markers are one of the most denial-prone categories in lab billing. Aetna's update to CPB 0352 touches a policy area where medical necessity documentation, test ordering rationale, and diagnosis coding all have to align perfectly — or you don't get paid. The full policy document does not list specific CPT or HCPCS codes in the data available at publication, so we'll flag that directly and tell you how to act on it.

Aetna Tumor Marker Coverage Policy: Medical Necessity Requirements 2026

Tumor marker billing is already a high-risk area. Aetna's CPB 0352 Aetna system is the controlling document for whether a given test gets paid — and modifications to it don't happen in a vacuum. When Aetna revises this policy, it usually means criteria have tightened, new markers have been reclassified, or documentation expectations have shifted.

The core of any Aetna tumor marker coverage policy is medical necessity. Aetna covers tumor markers when they meet specific clinical criteria — typically tied to cancer diagnosis, monitoring of known malignancy, or surveillance after treatment. Testing ordered for general screening in average-risk patients, or without a documented clinical rationale, will not meet medical necessity under this policy.

The specific revised criteria from the March 28, 2026 update are not available in the policy data at publication. Pull the full CPB 0352 document directly from Aetna's clinical policy bulletin library to confirm the exact changes. If you're billing for tumor markers on Aetna patients, do this before the effective date — not after you see your first denial.

Prior authorization requirements under this policy vary by marker and clinical indication. Some tumor markers require prior auth before the test is performed. Others are subject to retrospective review. You need to know which category each marker falls into for your patient population, because the prior authorization trigger and the medical necessity standard are two separate things — and both can generate a claim denial.

Aetna Tumor Marker Exclusions and Non-Covered Indications

This section reflects what Aetna historically excludes under its tumor marker coverage policy. Because the specific updated criteria from CPB 0352 are not available in the policy data at publication, treat these as the baseline — then verify against the actual revised document.

Aetna has consistently excluded tumor markers ordered for general cancer screening in asymptomatic, average-risk individuals. A PSA ordered outside of established prostate cancer screening criteria, or a CA-125 ordered without gynecologic symptoms or documented risk factors, will get denied. The test might be clinically reasonable to the ordering physician — Aetna's position is that it doesn't meet their coverage standard.

Markers used purely for investigational purposes also fall outside this coverage policy. If a marker is classified as experimental or investigational under CPB 0352, reimbursement is off the table regardless of diagnosis coding. The real issue here is that the line between "investigational" and "covered with criteria" shifts with each policy revision — which is exactly why the March 28, 2026 update matters.

Panels or reflex testing that bundles covered markers with non-covered markers can create partial denial situations. You may get reimbursement for some components and zero on others, with the claim processing creating reconciliation headaches downstream.

Coverage Indications at a Glance

The policy data available at publication does not include the full indication-level criteria from the updated CPB 0352. The table below reflects established tumor marker coverage patterns under Aetna policy. Verify each row against the actual CPB 0352 document before March 28, 2026 — especially for any markers your practice orders frequently.

Aetna Tumor Marker Billing Guidelines and Action Items 2026

Tumor marker billing requires more documentation precision than almost any other lab category. The margin for error is thin. Here's what to do before March 28, 2026.

CPT, HCPCS, and ICD-10 Codes for Tumor Markers Under CPB 0352

The policy data available at publication does not include specific CPT, HCPCS, or ICD-10 codes from the updated CPB 0352. This is unusual for a policy of this scope, and it means the complete code list needs to come directly from the Aetna clinical policy bulletin.

Do not assume your current code list is correct based on prior versions of this policy. Tumor marker CPT codes — which typically fall in the 86000-series for immunoassays and the 82000-series for specific chemistry markers — are subject to annual code set changes and payer-specific coverage assignment. The only reliable source for the current covered code list under CPB 0352 is the actual policy document.

What to Look For in the CPB 0352 Document

When you pull the full policy, look for:

• The specific CPT codes listed as covered, non-covered, or investigational
• Any codes that moved between categories in this revision
• Frequency limitations attached to specific codes (e.g., how many times per year a serial marker is covered)
• ICD-10 pairings or restrictions tied to specific markers

Tumor marker billing is one of the areas where payers publish the most granular code-level criteria. Aetna's CPB 0352 typically includes this detail — it's just not captured in the data available to us at the time of this publication.

If you need a mapped code list before you can fully assess your exposure, your Aetna provider relations contact or your billing consultant should be your next call.